DIRS.INFO The most relevant business & tech news

☆ Daiichi Sankyo shares growth projections, says its oncology business is a 'growth driver'
▼ + stars: | 2024-04-26 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDaiichi Sankyo shares growth projections, says its oncology business is a 'growth driver'Hiroyuki Okuzawa, president and COO of the Japanese pharma company, discusses the company's results and growth projections.

Persons: Hiroyuki Okuzawa Organizations: Japanese pharma

☆ Wells Fargo becomes bullish on this biotech company
▼ + stars: | 2024-04-24 | by ( Hakyung Kim | ) www.cnbc.com time to read: +1 min

Neurocrine Biosciences ' drug pipeline is turning a corner and the company will be "knocking on the doors of the large-cap club" soon, according to Wells Fargo. Bansal forecasts the company's congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.5 billion in peak sales, topping his prior $1.1 billion estimate. "We think [the] Crinecerfont [opportunity] is underappreciated as the Street is only giving credit for $500-$700M peak opportunity." Bansal said this drug could open "a whole new chapter" of a $1.2 billion peak sales opportunity. The NBI-'845 treatment could be "another blockbuster opportunity," Bansal said, citing the treatment's once-daily administration as a factor in his assessment.

Persons: Mohit, Bansal, Takeda, — CNBC's Michael Bloom Organizations: Biosciences Locations: Wells Fargo

☆ China pledges to expand market access at annual trade fair amid foreign criticism
▼ + stars: | 2023-11-05 | by ( Brenda Goh | ) www.reuters.com time to read: +3 min

SHANGHAI, China (Reuters) -China will further expand market access and increase imports, its premier told a trade fair in Shanghai on Sunday, amid criticism from European firms who said they wanted to see more tangible improvement in the country’s business environment. China will promote coordinated development of trade in goods and services, protect an international business environment, and relax market access including lifting restrictions on foreign investment in manufacturing, he said. The import expo was launched by President Xi Jinping in 2018 to promote China’s free trade credentials and counter criticism of its trade surplus with many countries. China’s imports have slumped this year amid a slowdown in the world’s second largest economy, although data released last month indicated that the downtrend could be starting to ease. China will “actively promote” its application to join the Comprehensive Progressive Trans-Pacific Partnership (CPTPP), Li also said in his speech on Sunday.

Persons: Li Qiang, Tingshu Wang, ” Li, Xi Jinping, Li, Anthony Albanese, “ Organizations: Hangzhou Olympic Sports Centre, China, European Chamber of Commerce, Micron Technology, Nestle, Burberry, Australian, Pacific Locations: SHANGHAI, China, Shanghai, Hangzhou, Afghan, Australia, United States, Taiwan, Ukraine, Costa Rica, Uruguay, Ecuador, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, Vietnam, Britain

☆ China Arrests Japanese Executive Despite Tokyo’s Appeals
▼ + stars: | 2023-10-19 | by ( Miho Inada | ) www.wsj.com time to read: 1 min

The arrested Astellas Pharma executive disappeared in late March. Photo: Akio Kon/Bloomberg NewsTOKYO—China formally arrested a Japanese pharmaceutical executive who had been detained since March, Tokyo said Thursday, in a move likely to further chill business travel to the nation. Hirokazu Matsuno , Japan’s chief cabinet secretary, said the Astellas Pharma executive, whom China has previously identified as Hiroshi Nishiyama , was arrested in mid-October. Matsuno said Tokyo had made strong appeals to Beijing for the early release of the executive and would continue doing so.

Persons: Astellas, Akio Kon, Hirokazu, Hiroshi Nishiyama, Matsuno Organizations: Astellas Pharma, Bloomberg News TOKYO Locations: China, Tokyo, Beijing

☆ Stocks making the biggest moves premarket: Rivian, Clorox, Vestis, Chevron and more
▼ + stars: | 2023-10-05 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines in premarket trading. Rivian — Shares of the electric vehicle maker plunged 8.7% after Rivian announced a $1.5 billion convertible bond sale and issued disappointing guidance for the third quarter. Energy stocks — Shares of oil firms Occidental Petroleum , Chevron and ExxonMobil were all lower in premarket trading, as crude prices added to Wednesday's steep declines. Clorox — Shares slipped 4.4% in premarket trading Thursday, a day after the product maker offered weaker guidance for the fiscal first quarter than analysts expected. UWM Holdings — Shares of the mortgage company rose 4.3% in premarket trading after a BTIG upgrade to buy from neutral.

Persons: Rivian, Raymond James, BTIG, Oliver Davies, Vestis, —, Alex Harring, Pia Singh, Jesse Pound Organizations: of Manhattan, StreetAccount, Energy, Occidental Petroleum, Chevron, ExxonMobil, Occidental, Holdings, United Wholesale Mortgage, Orchard Therapeutics, Kirin, Redburn Locations: Meatpacking, New York City, Chevron, Aramark

☆ Stocks making the biggest moves midday: Rivian, Orchard Therapeutics, Lamb Weston and more
▼ + stars: | 2023-10-05 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

Rivian said it anticipates revenue to range between $1.29 billion and $1.33 billion, versus the $1.3 billion forecast by analysts polled by LSEG, formerly known as Refinitiv. Clorox — Shares dropped 7.7% on Thursday, one day after the product maker offered worse fiscal first-quarter guidance than analysts polled by FactSet expected. Oculis — Shares rose 3.4% after Stifel initiated coverage of the biopharma company with a buy rating and $35 target price. Johnson & Johnson — Shares of the health-care giant added 0.8% in midday trading after RBC initiated company coverage with an outperform rating. Instacart — Instacart fell 2.9% after Bernstein initiated coverage of the company at a market perform rating, noting that increased competition challenged the delivery company's strong digital advertising business.

Persons: Rivian, Clorox, FactSet, Kyowa Kirin, Vestis, Oculis, Wedbush, Shagun Singh, Lamb Weston — Lamb Weston, Tom Werner, Instacart — Instacart, Bernstein, — CNBC's Brian Evans, Alex Harring, Tanaya Macheel, Sarah Min, Jesse Pound, Pia Singh, Samantha Subin, Michelle Fox Theobald Organizations: Rivian, Rivian Automotive, LSEG, Exxon Mobil —, UWM Holdings, BTIG, Orchard Therapeutics, Kyowa, Redburn, JPMorgan, Carrier, Bank of America, Johnson, RBC, Constellation Locations: Aramark, Europe

☆ 3 health-care stocks are in the headlines. How the news impacts our investments
▼ + stars: | 2023-07-13 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

In April, alongside its first-quarter results, J & J raised its full-year sales guidance by about $1 billion and its earnings-per-share outlook by 15 cents. Clearing this overhang would help reduce the discount at which J & J shares to pharmaceutical peers, the firm said. The Club's take: JPMorgan's thinking on J & J aligns quite closely with our own. The dark cloud of talc lawsuits continues to keep a lid on J & J's stock price. Joaquin Duato, chief executive officer of Johnson & Johnson, at the company's headquarters in New Brunswick, New Jersey, U.S., on Thursday, April 21, 2022.

Persons: Johnson, Eli Lilly, J, Wells, Wells Fargo, Eli Lilly's, —, Eisai, Biogen, Bloomberg, we've, Jim Cramer's, Jim Cramer, Jim, Joaquin Duato, Amir Hamia Organizations: Johnson, JPMorgan, pharma, U.S ., Humana, UnitedHealth, Bloomberg, U.S, Mayo Clinic, Club, GE Healthcare, CNBC, Getty, & $ Locations: U.S, California, Wells Fargo, Rochester , Minnesota, New Brunswick , New Jersey

☆ Biogen shares fall after Alzheimer’s drug approval. Here's what the pros are saying
▼ + stars: | 2023-07-07 | by ( Joshua Natoli | ) www.cnbc.com time to read: 1 min

Market Movers rounded up the best reactions from investors and analysts on Biogen . The experts discussed the biotech company after the Food and Drug Administration approved its Alzheimer's treatment Leqembi , paving the way for broader Medicare coverage. The drug slowed cognitive decline in trials, but poses risks of brain swelling and bleeding and comes with a $26,500 per year price tag. Biogen collaborated with Japanese pharmaceutical company Eisai to make Leqembi. Despite the approval, Biogen shares slid more than 3% by Friday's market close and are down nearly 10% over the past month.

Persons: Biogen Organizations: Food and Drug Administration

Signage for Eisai Co. at the company's headquarters in Tokyo, Japan, on Friday, Feb. 3, 2023. Bloomberg | Bloomberg | Getty ImagesShares of Japanese pharmaceutical giant Eisai sank Friday after the company's Alzheimer's drug was formally approved by U.S. regulators overnight, prompting questions over investor sentiment surrounding the move. Eisai shares closed 4.67% lower after paring some of its earlier losses. Leqembi is the first Alzheimer's antibody treatment to receive full FDA approval. "The odds for brain swelling and hemorrhage are far higher than any actual improvement," Espay, who launched a petition in June calling for the Alzheimer's treatment to not get full approval, told NBC News.

Persons: Biogen, Dr, Alberto Espay, Espay, Ivan Cheung, CNBC's, Cheung Organizations: Bloomberg, Getty, U.S, . Food, Medicare, University of Cincinnati College of, NBC News, Eisai U.S Locations: Tokyo, Japan, Eisai

☆ Two health-care stocks are in the headlines. How the news impacts our investments
▼ + stars: | 2023-07-07 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +9 min

Here's a deeper look at the headlines and their implications for our investment theses in these two health-care companies. The Club's take: The first-of-their-kind FDA and CMS actions came in generally as anticipated, and represent incremental positives for Eli Lilly. That's why some of the decline seen Friday in Eli Lilly shares – down over 2%, to around $453 each – could simply represent a sell-the-news situation. Eli Lilly has said donanemab could be approved by the FDA late this year or in early 2024. Our expectations around donanemab sales also are measured, and the drug is not the primary driver of our multiyear optimism for Eli Lilly.

Persons: Eli Lilly, Eli Lilly's donanemab, Leqembi —, Biogen, —, Lilly's, That's, Donanemab, Lilly, donanemab, that's, Lisa Gill, UnitedHealth, Humana, Gill, What's, We'll, Jim Cramer's, Jim Cramer, Jim Organizations: Club, Drug Administration, Medicare, Medicaid Services, FDA, GE Healthcare, Humana, JPMorgan, CNBC Locations: Massachusetts

☆ Alibaba and more: Morgan Stanley names 5 global stocks with at least 50% upside
▼ + stars: | 2023-06-19 | by ( Ganesh Rao | ) www.cnbc.com time to read: +4 min

Morgan Stanley expects five of its top Asia stock picks to rise by more than 50% over the next 12 months. Alibaba Alibaba Group, the Chinese technology giant that's also listed in the United States, is making significant progress in its restructuring process, according to Morgan Stanley. "The likelihood of generics being immediately released in May 2024 is low," Morgan Stanley analysts Shinichiro Muraoka and Jaeheon Lee said in a note to clients on June 12. Sea Despite the challenges from inflation and post-pandemic economic reopenings, Morgan Stanley still sees long-term potential in Sea Limited . JD.com Morgan Stanley highlighted JD.com , a leading Chinese e-commerce company, for its potential growth as Chinese consumer spending picks up.

Persons: Morgan Stanley, Morgan Stanley's, Morgan, Gary Yu, Astellas, Astellas Pharma Morgan Stanley, Shinichiro Muraoka, Jaeheon Lee, JD.com Morgan Stanley, Eddy Wang, Ping, Jenny Jiang Organizations: Asia, Alibaba, Street, Astellas Pharma, Ping An Insurance Locations: Asia, Asia Pacific, Japan, China, India, United States, U.S, Singapore

☆ Upside for Japanese pharma firm Eisai is still 'very, very strong,' says financial services firm
▼ + stars: | 2023-06-08 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailUpside for Japanese pharma firm Eisai is still 'very, very strong,' says financial services firmJesper Koll of Monex Group says Eisai is "not a defensive play" and it's "turning into a growth play."

Persons: Jesper Koll Organizations: Japanese pharma, Monex

We are selling 50 shares of Eli Lilly (LLY) at roughly $442 each. Following Monday's trade, Jim Cramer's Charitable Trust will own 150 shares of LLY, decreasing its weighting in the portfolio to about 2.5% from 3.33%. We're taking some Eli Lilly off the table Monday afternoon on the stock's breakout to another new all-time high. The FDA in early January granted accelerated approval to a drug similar to donanemab, which was developed by Japanese pharmaceutical firm Eisai and U.S.-based partner Biogen (BIIB). Like Pfizer's drug, Lilly is working on an oral type-2 diabetes and chronic weight management drug called orforglipron, which could be similar to the Mounjaro injectable.

☆ Citi names its top biotech and pharma stock picks, giving one nearly 90% upside
▼ + stars: | 2023-05-17 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

The healthcare sector outperformed in Europe, India and China last month, according to Citi, which named its top picks worldwide. It gave Amylyx a price target of $53, giving it upside of around 88% from current levels. It gave Beam a price target of $60, implying upside of around 67%. Other European picks from Citi include Swiss healthcare company Roche and British pharma and biotech firm AstraZeneca . Asia stocks In Asia, Citi named Japanese pharmaceutical company Daiichi Sankyo , South Korean biotech firm Samsung Biologics and China's Wuxi Biologics as top picks.

We're initiating a position in GE Healthcare (GEHC), buying 325 shares at roughly $79 each. GE Healthcare is the global leader in medical imaging, diagnostics, and digital solutions. GE Healthcare is one of the global leaders in Precision Diagnostics with an industry-leading injectable pharmaceutical portfolio in contrast media and molecular imaging. GE Healthcare is one of a few companies that offer a full suite of products and solutions to support patients. GEHC YTD mountain GE Healthcare YTD performance Analysts see GE Healthcare growing EPS to $4.33 in 2024, about a 15% increase from this year's outlook.

☆ Positive Alzheimer's drug trial data pushes Eli Lilly shares to another all-time high and brightens our outlook
▼ + stars: | 2023-05-03 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

LLY 1Y mountain Shares of Eli Lilly over the past 12 months. The FDA granted accelerated approval to an anti-amyloid drug — developed by Japanese pharmaceutical firm Eisai and U.S.-based partner Biogen (BIIB) — in early January. For Eli Lilly, specifically, Seigerman said the donanemab data appears to be a "home run." Eli Lilly said two participants in the Phase 3 trial died due to ARIA side effects, while a third patient did after a serious ARIA incident. The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.

☆ Beijing’s Bain Raid, Espionage Law Are Self-Sabotage
▼ + stars: | 2023-04-28 | by ( Nathaniel Taplin | ) www.wsj.com time to read: 1 min

It’s Party time. Photo: Ng Han Guan/Associated PressChina’s economy is bouncing back quicker than expected. So, unfortunately, are the sort of heavy-handed policies that spooked investors during China’s last big expansion in 2021. On Wednesday China updated its counterespionage statute to cover all “documents, data, materials or items related to national security,” a considerably wider remit than the previous “state secrets and intelligence.” Recent weeks have also brought a raid of Bain & Co.’s Shanghai offices, the detention of Beijing staff at New York-based due diligence firm Mintz Group, and the arrest of a Japanese pharmaceuticals employee for alleged spying.

Piper Sandler said several positive catalysts are in sight for Biogen over the next several quarters. The firm named the foremost catalyst for Biogen as Alzheimer's treatment Leqembi , which it co-developed with Japanese pharmaceutical company Eisai. Specifically, while share today is minimal (0.7% of patients), docs project this share to almost quadruple within 6 months," Raymond wrote in a Monday note. Aduhelm is the controversial Alzheimer's treatment developed by Biogen and Eisai, whose sales fell below Wall Street's expectations as its efficacy was called into question. "For our part, we think Leqembi has set a high bar – especially with regard to safety," said Raymond.

☆ Japan Restricts Semiconductor-Equipment Exports as Ties With China Chill
▼ + stars: | 2023-03-31 | by ( Peter Landers | ) www.wsj.com time to read: 1 min

TOKYO—Japan said it would restrict the export of advanced semiconductor equipment, a measure that could hamper development of China’s industry and marks a further cooling of relations after the detention of a Japanese pharmaceutical-company employee in Beijing. Foreign Minister Yoshimasa Hayashi will visit Beijing Saturday to meet with his Chinese counterpart, the Japanese government said Friday. It didn’t disclose the purpose of the visit, the first by a Japanese foreign minister to China since December 2019, but Tokyo has called for the quick release of the detained Japanese man.

☆ Japan Curbs Semiconductor-Gear Exports as Ties With China Chill
▼ + stars: | 2023-03-31 | by ( Peter Landers | ) www.wsj.com time to read: 1 min

☆ 9 psychedelics startups that are winning over top venture investors
▼ + stars: | 2023-03-29 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +1 min

Generally, mainstream investors have avoided companies developing psychedelic compounds. Despite raising hundreds of millions of dollars in recent years to develop psychedelic compounds like psilocybin through clinical trials, startups operating in the space have struggled to gain momentum among biotech investors and other venture firms. However, a handful of companies have successfully garnered funding and interest from mainstream investors. Psychedelics companies, including Atai Life Sciences, Compass Pathways, and Mindset Pharma have all received backing from Otsuka, a Japanese pharmaceutical company. Here are the psychedelics startups that have won over mainstream investors, listed in alphabetical order:

☆ See the 14-slide pitch deck Labviva used to raise $20 million to overhaul a crucial but overlooked task for Big Pharma
▼ + stars: | 2023-03-27 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +1 min

The startup just raised $20 million to help expand its team and platform. Siamak Baharloo says there's a big time-consuming task that's taking researchers away from doing science in their labs: finding and buying the right supplies for their experiments. He added that the company expects to see $150 million in purchases on its platform in 2023. Labviva said on Monday that it had raised $20 million from investors in a Series A round led by Biospring Partners, bringing the company's total capital raised to $30 million. See the pitch deck Labviva used to raise its series A round:

☆ Japanese man detained in China is Astellas Pharma employee
▼ + stars: | 2023-03-26 | by ( ) www.reuters.com time to read: +1 min

TOKYO, March 26 (Reuters) - A Japanese man detained in China is an employee of Astellas Pharma Inc (4503.T), a company spokesperson told Reuters on Sunday. The company did not identify the employee and the spokesperson said it was not clear as to why he had been detained. Kyodo and other Japanese media reported on Saturday that a Japanese man in his 50s was taken into custody in Beijing this month for an alleged violation of Chinese law. But China had not fully explained what prompted authorities in Beijing to detain the man, media said. The Japanese government had asked Chinese authorities to release the man, media reported.

☆ Medicare rejects Alzheimer's Association request for unrestricted coverage of treatments like Leqembi
▼ + stars: | 2023-02-23 | by ( Spencer Kimball | ) www.cnbc.com time to read: +6 min

The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Due to the drug's high price and Medicare's coverage restrictions, seniors are unable to access the treatment. The letter the Alzheimer's Association sent to CMS in December calling for unrestricted coverage was signed by more than 200 researchers and experts. CMS said it would provide broader coverage of Leqembi on the same day should the FDA fully approve the treatment. Medicare adopted the coverage restrictions after controversy over the Alzheimer's antibody treatment Aduhelm, which was also developed by Eisai and Biogen.

☆ Pharma CEOs say Mark Cuban's effort to upend the drug industry is 'a really great idea' but will be difficult to pull off
▼ + stars: | 2023-01-25 | by ( Yeji Jesse Lee | Andrew Dunn | ) www.businessinsider.com time to read: +7 min

Biopharma CEOs say his company Cost Plus Drugs could remove costs from the distribution system. Cuban told Insider in an email that he believed the company's pricing transparency was "an absolute positive for patients." The company started its pharmacy services last year and quickly racked up over 1 million accounts, Cuban told Insider recently. Cost Plus Drugs is focused on bringing down the price of generic medications, which no longer have patent protections but can still be expensive. Cuban told Insider that EQRx was in a "different business" than what he's attempting to build out.

Search resuls for: "Japanese pharma"

25 mentions found